Literature DB >> 14603267

Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers.

Celia J A Morgan1, Ali Mofeez, Brigitta Brandner, Lesley Bromley, H Valerie Curran.   

Abstract

N-methyl-D-aspartate (NMDA) receptor antagonists have been demonstrated to induce schizophrenia-like symptoms and cognitive impairment in humans. The NMDA receptor has been strongly implicated in memory, but research to date on the effects of NMDA antagonists has examined only some aspects of human memory functions. This study used a double-blind, placebo-controlled, independent groups design with 54 healthy volunteers to examine the effects of infusions of two doses (0.4, 0.8 mg/kg) of the NMDA antagonist ketamine upon the five human memory systems, aspects of executive functioning and schizophrenia-like and dissociative symptoms. Ketamine produced a dose-dependent impairment to episodic and working memory and a slowing of semantic processing. Ketamine also impaired recognition memory and procedural learning. Attention, perceptual priming and executive functioning were not affected following the drug. In addition, ketamine induced schizophrenia-like and dissociative symptoms, which were not correlated with the cognitive measures. These data suggest that, in humans, ketamine produces a selective pattern of impairments to working, episodic, and procedural memory but not to perceptual priming, attention or aspects of executive functioning.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14603267     DOI: 10.1038/sj.npp.1300342

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  79 in total

Review 1.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

3.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

Review 4.  Low dose acute alcohol effects on GABA A receptor subtypes.

Authors:  Martin Wallner; H Jacob Hanchar; Richard W Olsen
Journal:  Pharmacol Ther       Date:  2006-07-11       Impact factor: 12.310

Review 5.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

6.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

7.  The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.

Authors:  Nikolaos Pitsikas; Athina Markou
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

8.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

9.  Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.

Authors:  Georgia Georgiadou; Vasilios Grivas; Petros A Tarantilis; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

10.  Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors.

Authors:  Ting-Ting Duan; Ji-Wei Tan; Qiang Yuan; Jun Cao; Qi-Xin Zhou; Lin Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.